San Carlos, CA ; 03/24/2020
Amount Funded: $123 Million
Type: Series C
Lead Investor: Decheng Capital
Participating Investor(s): Oceanpine Capital, other unlisted investors
Total Funding to Date: $158 Million
Company Description: Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. APX005M and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product or product candidates discovered using APXiMAB are currently commercially available or in clinical development, either internally by Apexigen or by its licensees.
What funding will be used for: Support current development of key immunotheraputic products, development of company’s pipeline of therapies.
“Over the past year and a half we have made exceptional progress and generated compelling data from our ongoing clinical trials with APX005M, which to date have enrolled and treated over 400 cancer patients. In addition, the regulatory approval and commercial launch of a licensed product, the first for a product that emerged from our APXiMAB™ discovery platform, provided further validation for the platform. We welcome the support of both new and existing investors in our efforts to advance a new generation of immunotherapeutic agents to treat a diverse range of malignancies.”
-Xiaodong Yang, M. D. , Ph.D., President/CEO, Apexigen
Photo credit: PRNewswire/Apexigen
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.